Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection  Uchenna H. Iloeje, Hwai–I. Yang, Chin–Lan Jen, Jun Su, Li–Yu Wang, San–Lin You, Chien–Jen Chen  Clinical Gastroenterology and Hepatology  Volume 5, Issue 8, Pages 921-931 (August 2007) DOI: 10.1016/j.cgh.2007.06.015 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Study design and flow chart. Clinical Gastroenterology and Hepatology 2007 5, 921-931DOI: (10.1016/j.cgh.2007.06.015) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Total mortality according to HBsAg serostatus (n = 22,472). Clinical Gastroenterology and Hepatology 2007 5, 921-931DOI: (10.1016/j.cgh.2007.06.015) Copyright © 2007 AGA Institute Terms and Conditions

Figure 3 (A) Total mortality according to baseline HBV DNA level in HBsAg-positive subjects without evidence of HCV infection (n = 3653). (B) Liver-related mortality according to baseline HBV DNA level in HBsAg-positive subjects without evidence of HCV infection (n = 3653). (C) Non–liver-related mortality according to baseline HBV DNA level in HBsAg-positive subjects without evidence of HCV infection (n = 3653). Clinical Gastroenterology and Hepatology 2007 5, 921-931DOI: (10.1016/j.cgh.2007.06.015) Copyright © 2007 AGA Institute Terms and Conditions

Figure 3 (A) Total mortality according to baseline HBV DNA level in HBsAg-positive subjects without evidence of HCV infection (n = 3653). (B) Liver-related mortality according to baseline HBV DNA level in HBsAg-positive subjects without evidence of HCV infection (n = 3653). (C) Non–liver-related mortality according to baseline HBV DNA level in HBsAg-positive subjects without evidence of HCV infection (n = 3653). Clinical Gastroenterology and Hepatology 2007 5, 921-931DOI: (10.1016/j.cgh.2007.06.015) Copyright © 2007 AGA Institute Terms and Conditions